The role of GSK-3 in mood disorders: Preliminary data from an experimental study

• Published in: European psychiatry Vol. 64; no. S1; pp. S382 - S383
• Main Authors: Salvo, G. Di, Rosso, G., Hoxha, E., Teobaldi, E., Balbo, I., Tempia, F., Maina, G.
• Format: Journal Article
• Language: English
• Published: Paris Cambridge University Press 01.04.2021
• Subjects: Abstract; Biomarkers; Differential Diagnosis; E-Poster Presentation; Emotional disorders; GSK-3; Mood disorder; Mood disorders
• ISSN: 0924-9338; 1778-3585
• DOI: 10.1192/j.eurpsy.2021.1025

Introduction The identification of potential biomarkers is crucial to improve the management and treatment of mood disorders. Glycogen synthase kinase-3 (GSK-3) is a multifunctional enzyme with an important role in the etiology of mood disorders. Recent findings suggested GSK-3 as a putative biomarker in mood disorders. Objectives The aims of the study are: - to evaluate GSK3 as potential biomarker for differential diagnosis (MDD and BD); - to analyze the regulation of GSK3 by psychopharmacological treatments. Methods Patients included fulfill the following criteria: (a) principal diagnosis of MDD or BD (DSM-5); (b) age ≥ 18 years; (c) drug-free for at least 4 weeks before the inclusion. For each patient included a healthy control is enrolled, matched by gender and age. All included subjects at the study entry point (t0) are assessed through: - semistructured clinical interview and clinical rating scales (Hamilton Depression Rating Scale, Hamilton Anxiety Rating Scale; Young Mania Rating Scale, Clinical Global Impression) - blood draw, to measure GSK-3 levels Patients with MDD or BD are assessed again after 1 week (T1) and after 2 month (T2) of specific pharmacological treatment. Results So far, we enrolled 16 patients and 16 healthy controls. The enrollment is still ongoing. Conclusions We expect to find GSK-3 levels differently expressed between healthy controls, patients with DDM and patients with BD. This finding would be crucial as it could contribute to the improvement of differential diagnosis. Moreover, we expect to observe a change in GSK-3 levels after psychopharmacological treatments.